ID: ALA5271202

Max Phase: Preclinical

Molecular Formula: C23H24ClN3O2

Molecular Weight: 409.92

Associated Items:

Representations

Canonical SMILES:  O=C(CCc1ccccc1)N1CCC(Cn2cnc3cc(Cl)ccc3c2=O)CC1

Standard InChI:  InChI=1S/C23H24ClN3O2/c24-19-7-8-20-21(14-19)25-16-27(23(20)29)15-18-10-12-26(13-11-18)22(28)9-6-17-4-2-1-3-5-17/h1-5,7-8,14,16,18H,6,9-13,15H2

Standard InChI Key:  RMYINDHVGQFJRO-UHFFFAOYSA-N

Associated Targets(Human)

Ubiquitin carboxyl-terminal hydrolase 7 837 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 409.92Molecular Weight (Monoisotopic): 409.1557AlogP: 3.92#Rotatable Bonds: 5
Polar Surface Area: 55.20Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.81CX LogP: 3.55CX LogD: 3.55
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.64Np Likeness Score: -1.28

References

1. Li P, Liu HM..  (2020)  Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.,  191  [PMID:32092586] [10.1016/j.ejmech.2020.112107]

Source